- Home
- CTO vs PLRX Comparison
CTO vs PLRX Comparison
Compare CTO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | PLRX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.2M | 61.1M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | PLRX |
|---|---|---|
| Price | $20.20 | $0.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $24.00 | $2.67 |
| AVG Volume (30 Days) | ★ 345.2K | 344.2K |
| Earning Date | 10-27-2026 | 11-17-2026 |
| Dividend Yield | ★ 7.54% | N/A |
| EPS Growth | ★ 122.86 | 29.97 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $149,545,000.00 | N/A |
| Revenue This Year | $20.14 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | $68.20 | ★ N/A |
| Revenue Growth | ★ 20.10 | N/A |
| 52 Week Low | $17.02 | $0.83 |
| 52 Week High | $22.71 | $1.82 |
Technical Indicators
Market Signals| Indicator | CTO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 31.54 |
| Support Level | $20.12 | N/A |
| Resistance Level | $20.88 | $0.90 |
| Average True Range (ATR) | 0.54 | 0.04 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 76.47 | 9.73 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.